D3

D3 is a Tokyo-based investment firm focusing on early-stage companies, particularly in the Series A stage. While their specific investment size is not disclosed, they have demonstrated interest in the biotechnology sector, as evidenced by their portfolio.

Notable among D3's investments is Shinobi Therapeutics, a biotech company that has raised $51 million. The firm's approach combines financial services with management consultancy, offering a blend of capital and strategic guidance to their portfolio companies. This dual expertise positions D3 as a value-added partner for startups seeking both funding and operational support.